TVTX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
224.6M
+32.4%
169.6M
+33.3%
127.2M
-1.9%
129.7M
-21.3%
164.9M
Cost of Revenue
2.9M
+31.9%
2.2M
+11.5%
1.9M
-23.6%
2.6M
+61.1%
1.6M
Gross Profit
221.7M
+32.4%
167.4M
+33.7%
125.2M
-1.5%
127.1M
-22.1%
163.3M
Operating Expenses
289.8M
+77.3%
163.5M
+0.8%
162.2M
+1.6%
159.6M
+15.3%
138.3M
R&D
183.4M
+204.3%
60.3M
+5.6%
57.1M
-1.3%
57.9M
+11.5%
51.9M
SG&A
98.4M
+2.4%
96.1M
+19.8%
80.3M
-21.1%
101.7M
+43.1%
71.0M
Operating Income
-68105000
-1822.4%
4.0M
+110.7%
-36915000
-13.8%
-32428000
-230.1%
24.9M
EBITDA
-62906000
-868.3%
8.2M
+170.0%
-11703000
+18.1%
-14291000
-135.1%
40.7M
Net Income
-52337000
-50.4%
-34797000
+6.2%
-37102000
-1459.5%
2.7M
-89.4%
25.7M
EPS (Basic)
$-0.55
-48.6%
$-0.37
+7.5%
$-0.40
-1433.3%
$0.03
-89.7%
$0.29
EPS (Diluted)
$-0.55
-48.6%
$-0.37
+7.5%
$-0.40
-1100.0%
$0.04
-85.7%
$0.28
Shares (Diluted)
94.6M
+1.2%
93.5M
+1.8%
91.9M
+19.4%
76.9M
-25.0%
102.6M
Travere Therapeutics (TVTX) — Financials